MG
STLN

Michael Gelband’s Starling Oncology STLN Stock Holding History

Michael Gelband’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Buy
33,644
+9,225
+38% +$38.8K ﹤0.01% 1429
2026
Q1 		$75K Sell
24,419
-92,907
-79% -$285K ﹤0.01% 1450
2025
Q4 		$418K Buy
117,326
+2,083
+2% +$7.72K ﹤0.01% 1216
2025
Q3 		$402K Buy
+115,243
New +$395K ﹤0.01% 1235
2022
Q2 		– Sell
-106,505
Closed -$759K – 2454
2022
Q1 		$759K Buy
106,505
+75,805
+247% +$511K 0.01% 1308
2021
Q4 		$299K Buy
+30,700
New +$273K ﹤0.01% 1657

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's STLN Position: Q2 2026 in Review

Michael Gelband increased its Starling Oncology (STLN) stake by 38% in Q2 2026, buying an estimated $38.8K and bringing the position to 33,644 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Michael Gelband first reported a position in STLN in Q4 2021 and has held it in 6 quarters since. The position peaked at $759K in Q1 2022. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Michael Gelband held 33,644 shares of Starling Oncology worth $183K as of Q2 2026.
  • Michael Gelband bought 9,225 Starling Oncology shares in Q2 2026, an estimated $38.8K.
  • Starling Oncology made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1429 holding.
  • Michael Gelband first reported a position in Starling Oncology in Q4 2021 and has held it in 6 quarters since.
  • Michael Gelband's Starling Oncology position peaked at $759K in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.